These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 27264278)
1. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
2. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic Multidose Preparation of a Ready-to-Use Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687 [No Abstract] [Full Text] [Related]
4. Preparation of Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436 [TBL] [Abstract][Full Text] [Related]
5. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643 [TBL] [Abstract][Full Text] [Related]
6. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
7. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
9. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178 [TBL] [Abstract][Full Text] [Related]
10. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
11. Safety of PSMA-Targeted Molecular Radioligand Therapy with Calais J; Czernin J; Thin P; Gartmann J; Nguyen K; Armstrong WR; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Dahlbom M; He B; Esfandiari R; Ranganathan D; Herrmann K; Eiber M; Fendler WP; Delpassand E J Nucl Med; 2021 Oct; 62(10):1447-1456. PubMed ID: 34272322 [TBL] [Abstract][Full Text] [Related]
12. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nautiyal A; Jha AK; Mithun S; Rangarajan V Nucl Med Commun; 2022 Apr; 43(4):369-377. PubMed ID: 35045551 [TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
14. Novel [ Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975 [TBL] [Abstract][Full Text] [Related]
15. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
16. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747 [TBL] [Abstract][Full Text] [Related]
17. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]